

Method for enzymatic preparation of homogentisate

The present invention relates to a novel method for enzymatic preparation of homogentisate, or 2,5-dihydroxyphenylacetic acid (hereafter HMO).

5 HMO is a known precursor of molecules termed ochronotic pigments which are melanin analogues. These brown molecules are, moreover, often cited as "melanin-like pigments" which find a varied application in cosmetics or the pharmaceutical industry. The addition
10 of melanin or melanin-like pigments to antisun milks would have an advantageous protective effect. To produce these ochronotic derivatives from HGA, the method is simple since the molecule self-oxidizes rapidly under alkaline conditions. Various methods for
15 enzymatic preparation of HMO from 1-phenylacetic acid or from tyrosine are described in the prior art (WO 93/08295 or EP 343 330), as well as the subsequent preparation of melanin.

It is also known that HMO is a compound which
20 is essential to plant life. In plant cells, HMO is the product of enzymatic transformation of 4-hydroxyphenylpyruvate (hereafter HPP) with 4-hydroxyphenylpyruvate dioxygenase (hereafter HPPD). Inhibitors of this enzyme are herbicidal compounds
25 which block the production of HMO in plant cells (Pallett K.E. et al. 1997 Pestic. Sci. 50 83-84). When plants of *Arabidopsis thaliana* for example, are

germinated on synthetic medium in the presence of an HPPD inhibitor, the plants will germinate, remain white and then die very rapidly. However, if HMO is added to the synthetic medium supplemented with an HPPD inhibitor, the plants will germinate normally and remain green as long as the medium contains HMO. It is thus also important to have HMO available to prevent deficiencies in plants which are linked to a natural or induced, in particular by HPPD inhibitors, metabolic dysfunction of HMO biosynthesis.

The present invention thus relates to a method for enzymatic preparation of HMO from HPP, and more particularly to a method for enzymatic preparation of HMO from HPPD-inhibitor-insensitive HPP.

The method according to the invention consists in carrying out, in a suitable reaction medium, the following enzymatic reactions:

- enzymatic conversion of HPP into 4-hydroxyphenylacetate (hereafter HPA) with a first suitable enzyme,

then

- enzymatic conversion of HPA into HMO with a second suitable enzyme.

The following first enzymatic reaction

4-hydroxyphenylpyruvate (HPP) --->

4-hydroxyphenylacetate (HPA)

is catalysed by a suitable HPP-oxidase. Such oxidases are found in many prokaryotic or eukaryotic species, in particular in bacteria which can grow on HPP as the

only carbon source, transforming it into HPA, more particularly in an *Arthrobacter* in which such an oxidase [lacuna] responsible for a step in tyrosine catabolism (Blakley, E.R. 1977 Canadian Journal of Microbiology 23 1128-1139).

The following second enzymatic reaction:

4-hydroxyphenylacetate (HPA) --->

homogentisate (HMO)

is catalysed by a suitable HPA-hydroxylase. Such
 10 hydroxylases are found in many prokaryotic or eukaryotic species, in particular in bacteria which can grow on HPA as the only carbon source, transforming it into HMO, more particularly in *Pseudomonas acidovorans*, often termed *Comamonas acidovorans* (Hareland, W.A. et
 15 al 1975 Journal of Bacteriology 121 272-285), in certain *Xanthobacter* (Van Den Tweel W.J.J. et al. 1986 Antonie van Leeuwenhoek 52 309-318), in *Pseudomonas alcaligenes* (Karigar C.S. and Pujar B.G. 1993 FEMS Microbiology Letters 110 59-64), in *Flavobacterium sp.*
 20 (Van Den Tweel W.J.J. et al. 1988 Arch Microbiol. 149 207-213), in *Bacillus subtilis* (Crawford R.L. 1978 FEMS Microbiology Letters 4 233-234), in *Nocardia sp.* DM1 (Raju S.G. and Vaidyanathan C.S. 1986 J. Indian Inst. Sci. 66 511-520) and in *Rhodococcus erythropolis*
 25 (Suemori A. et al. 1996 Journal of Fermentation And Bioengineering Vol. 81, No. 2 133-137).

The HPA-hydroxylase used in the method according to the invention is advantageously extracted from *Pseudomonas acidovorans*.

According to a preferential embodiment of the invention, both enzymatic reactions are carried out in the same reaction medium containing HPP, the two suitable enzymes being present together at the same time in the reaction medium.

The two suitable enzymes can be introduced into the suitable reaction medium in the form of protein extract, said protein extract being able to be crude or totally or partially purified, or alternatively they can be produced in situ by suitable biological organisms. They can thus be produced in situ by each biological organism which naturally produces the two enzymes, or alternatively by a single biological organism which has been modified so as to produce the two enzymes. This biological organism can be a bacterium, a yeast or a plant cell.

Since the two enzymes are insensitive to HPPD inhibitors, the method according to the invention can be performed in the presence of an HPPD inhibitor in the suitable reaction medium.

The suitable reaction medium consists of any aqueous medium in which the temperature, pH and ionic strength conditions are suitable for the enzymatic reactions. When the enzymes are produced in situ by one

or more biological organisms, the reaction medium is suitable for the growth of said organisms.

At the end of the reaction, HMO can be isolated from the reaction medium and purified, or left
 5 in the reaction medium. In this second case, the reaction medium containing HMO can be used as a nutrient medium for culturing plants, more particularly for culturing plants which exhibit a natural or induced, in particular by HPPD inhibitors, metabolic
 10 dysfunction of HMO biosynthesis.

The examples below make it possible to illustrate the invention, without however seeking to limit the scope thereof.

**Example 1: Production of HPA from HPP using a protein
 15 extract from *Arthrobacter***

Arthrobacter culture:

Arthrobacter globiformis is cultured at 28°C and 220 rpm for 20 hours in a 250-ml Erlenmeyer flask containing 50 ml of medium A supplemented with 0.1%
 20 L-tyrosine and 0.01% of yeast extract [medium A composed, in grams per litre, of KH_2PO_4 (1.5) $\text{K}_2\text{HPO}_4 \cdot 3\text{H}_2\text{O}$ (3.5) NH_4NO_3 (1) $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ (0.1) $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$ (0.01) $\text{NaMoO}_2 \cdot 7\text{H}_2\text{O}$ (0.01) $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$ (0.01) $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ (0.05)].

Extraction and assay of HPP-oxidase activity

25 A cell pellet is recovered from 2.1 litres of culture by centrifugation at 3000 xg for 15 min. The pellet is washed with distilled water and then

recentrifuged. All subsequent steps are carried out at 4°C.

The cell pellet, which is approximately 3.4 g, is resuspended in 7 ml of extraction buffer (0.05 M potassium phosphate pH 7.5, 0.1 mM TPP, 0.1 mM MgCl₂ and 5 mM mercaptoethanol) and sonicated twice at 23 kHz for 2.5 min. The resulting suspension is centrifuged at 44,000 ×g for 20 min. The harvested supernatant is again centrifuged at 100,000 ×g for 60 min. 0.7 ml of 2% protamine sulphate in the extraction buffer is added to the new 7-ml supernatant, followed by gentle stirring. The precipitate which forms is removed by a centrifugation at 20,000 ×g for 20 min. Ammonium sulphate is gradually added to the supernatant thus obtained so as to reach 60% saturation. This new preparation is stirred for 30 min., and the precipitate formed harvested by centrifugation at 20,000 ×g for 20 min. The pellet is redissolved in 0.5 ml of extraction buffer and aliquoted in 0.1-ml fractions, these fractions being kept at -80°C before use.

The HPP-oxidase activity is measured in a 96-well microtitration plate with 200 µl of reaction per well consisting of 149.8 µl of 67 mM sodium phosphate pH 7.4, 10 µl of 13.4 mM glutathione, 10 µl of 67 mM MgCl₂, 10 µl of 26.7 mM TPP, 10 µl of 67 µM FAD, 0.2 µl of protein (i.e. approximately 6 µg) and 10 µl of 2.5 mM HPP.

When an assay for inhibition by an HPPD inhibitor is carried out, 2 μ l of 10 mM 4-[4-trifluoromethyl-2-(methylsulphonyl)benzoyl]-5-cyclopropylisoxazole are added to a phosphate buffer containing 20% of DMSO.

The reaction is initiated by adding the substrate, HPP; it takes place at 30°C for 5 min. with stirring. The reaction is stopped by adding 33 μ l of 25% perchloric acid.

10 The plate is then centrifuged at 2000 rpm for 15 min., and the supernatant is analysed by HPLC. 50 μ l of the supernatant is injected onto a Spherisorb ODS2 column equilibrated with buffer A (5.5% acetonitrile, 0.1% TFA) at the flow rate of 1.5 ml/min.

15 The elution programme used is:

0 min.: 0% of buffer B (acetonitrile)

6 min.: 15% of buffer B

6.5 min.: 15% of buffer B

7 min.: 60% of buffer B

20 8 min.: 60% of buffer B

8.5 min.: 0% of buffer B

The detection is carried out at 276 nm.

The HPA produced by the enzymatic extract from HPP is compared with a reference consisting of commercial HPA, in terms of retention time and spectral absorption peak.

25

Results

The HPLC analysis shows that the protein extract extracted from *Arthrobacter globiformis* cultured on tyrosine as the major carbon source is
 5 capable of transforming the HPP into HPA (the molecule produced comigrates perfectly with the commercial reference HPA).

The enzyme responsible for this reaction is not inhibited by 100 μ M of HPPD inhibitor.

10 **Example 2: Production of HMO from HPA using a protein extract from *Pseudomonas***

Organism culture

Pseudomonas acidovorans is cultured at 28°C and 220 rpm for 20 hours in a 250-ml Erlenmeyer flask
 15 containing 50 ml of medium B supplemented with 0.15% HPA and 0.01% of nitrilotriacetic acid [medium B composed, in grams per litre, of NaH₂PO₄ (1) K₂HPO₄.3H₂O (4.25) NH₄Cl (2) FeSO₄.7H₂O (0.012) ZnSO₄.7H₂O (0.003) MnSO₄.7H₂O (0.003) CoSO₄.7H₂O (0.01) MgSO₄.7H₂O (0.2)].

20 Extraction and assay of HPA-hydroxylase activity

A cell pellet is recovered from 0.1 litre of culture by centrifugation at 7500 \times g for 10 min. The pellet is washed with distilled water and then
 25 recentrifuged. All subsequent steps are carried out at 4°C.

The cell pellet, which is approximately 0.5 g, is resuspended in 1.5 ml of extraction buffer

(0.1 M potassium phosphate pH 7.2, 1 mM DTE and 5 mM MgSO₄) and sonicated twice at 23 kHz for 2.5 min. The resulting suspension is centrifuged at 44,000 ×g for 20 min. The harvested supernatant is again centrifuged at 100,000 ×g for 60 min. The new supernatant is aliquoted in 0.1-ml fractions, these fractions being kept at -80°C before use.

The HPA-hydroxylase activity is measured in a 96-well microtitration plate with 200 µl of reaction per well consisting of 150 µl of 0.1 M sodium phosphate pH 7.2, 10 µl of 20 mM DTE, 10 µl of 3 mM NADH, 15 µl of 67 µM FAD, 10 µl of protein (i.e. approximately 7 µg) and 5 µl of 10 mM HPA.

When an assay for inhibition by an HPPD inhibitor is carried out, 2 µl of 10 mM 4-[4-trifluoromethyl-2-(methylsulphonyl)benzoyl]-5-cyclopropylisoxazole are added to a phosphate buffer containing 20% of DMSO.

The reaction is initiated by adding the substrate, HPA; it takes place at 30°C for 5 min. with stirring. The reaction is stopped by adding 33 µl of 25% perchloric acid.

The plate is then centrifuged at 2000 rpm for 15 min., and the supernatant is analysed by HPLC. 10 µl of the supernatant is injected onto a Spherisorb ODS2 column equilibrated with buffer A (5.5% acetonitrile, 0.1% TFA) at the flow rate of 1.5 ml/min.

The elution programme used is:

0 min.: 0% of buffer B (acetonitrile)
0.8 min.: 0% of buffer B
1 min.: 60% of buffer B
1.7 min.: 60% of buffer B
5 1.9 min.: 0% of buffer B
5 min.: 0% of buffer B

The detection is carried out at 292 nm.

The HMO produced by the enzymatic extract from HPA is compared with a reference consisting of
10 commercial HMO, in terms of retention time and spectral absorption peak.

Results

The HPLC analysis made it possible to show that the protein extract extracted from *Pseudomonas*
15 *acidovorans* is capable of transforming the HPA into HMO (the molecule produced comigrates perfectly with the commercial reference HMO).

The enzyme responsible for this reaction is not inhibited under our assay conditions by 100 μ M of
20 HPPD inhibitor.

Example 3: Production of HMO from HPP using a protein extract from *Arthrobacter* and from *Pseudomonas*

HPA-hydroxylase activity-coupled HPP-oxidase
25 activity

The HPA-hydroxylase activity-coupled HPP-oxidase activity is measured in a 96-well microtitration plate with 200 μ l of reaction per well

consisting of 100 μ l of 100 mM sodium phosphate pH 7.2,
10 μ l of 20 mM DTE, 10 μ l of 3 mM NADH, 15 μ l of 67 μ M
FAD, 10 μ l of 13.4 mM glutathione, 10 μ l of 67 mM $MgCl_2$,
10 μ l of 26.7 mM TPP, 2 μ l of HPP-oxidase extract (i.e.
5 approximately 60 μ g), 25 μ l of HPA-hydroxylase extract
(i.e. approximately 18 μ g) and 10 μ l of 10 mM HPP.

The reaction is initiated by adding the
substrate, HPP; it takes place at 30°C for 30 min. with
stirring. The reaction is stopped by adding 33 μ l of
10 25% perchloric acid.

The plate is then centrifuged at 2000 rpm for
15 min., and the supernatant is analysed by HPLC. 25 μ l
of the supernatant is injected onto a Spherisorb ODS2
column equilibrated with buffer A (5.5% acetonitrile,
15 0.1% TFA) at the flow rate of 1.5 ml/min.

The elution programme used is:

0 min.: 0% of buffer B (acetonitrile)
6 min.: 15% of buffer B
6.5 min.: 15% of buffer B
20 7 min.: 60% of buffer B
8 min.: 60% of buffer B
8.5 min.: 0% of buffer B

The detection is carried out at 276 nm and
292 nm simultaneously.

25 Results

The HPLC analysis made it possible to show
that the protein extract extracted from *Arthrobacter*
globiformis combined with that from *Pseudomonas*

acidovorans is capable of simultaneously transforming HPP into HMO (the molecule produced comigrates perfectly with the commercial reference HMO).